Acyclovir is a synthetic analog of the purine nucleoside, guanosine, with potent antiviral activity against herpes simplex viruses type 1 and 2, varicella-zoster virus and other viruses. After conversion in vivo to the active metabolite acyclovir triphosphate, acyclovir competitively inhibits viral DNA polymerase, incorporates into and terminates the growing viral DNA chain, and inactivates viral DNA polymerase. The greater antiviral activity of acyclovir against HSV compared to VZV is due to its more efficient phosphorylation by the thymidine kinase of HSV.
Persons who have had chicken pox are prone to develop shingles with the Herpes zoster virus that lays dormant within them. A new study has shown that getting shingles - a painful skin condition caused by the virus could also raise the risk of heart disease such as heart attacks and strokes in individuals. The study was published in the Journal of the American College of Cardiology.
Slayback Pharma LLC is pleased to announce the launch of Generic Zovirax Ointment (Acyclovir Ointment) 5%, by its out-licensee - Sandoz (Fougera). Slayback had developed the product and out-licensed the sales and marketing rights to Sandoz.
In a study appearing in the December 20 issue of JAMA, Anna Wald, M.D., M.P.H., of the University of Washington & Fred Hutchinson Cancer Research Center, Seattle, and colleagues compared the medications pritelivir and valacyclovir for reducing genital herpes simplex virus shedding and lesions in persons with recurrent genital herpes.
Ethosomes are ethanolic nanovesicles that possess abundant amount of ethanol in its core which provides fluidity to the lipid bilayers and thus by this effect, improves the delivery of molecules into the deep skin layers.
Luminex Corporation today announced that it has received FDA clearance for the company's ARIES® System and ARIES HSV 1&2 Assay.
Researchers at University Jean Monnet of Saint-Etienne, France have succeeded in developing a vaginal silicone ring that delivers molecules that act on both HIV and herpes virus. This research is presented at the 55th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC/ICC).
NanoViricides, Inc., a nanomedicine company developing anti-viral drugs, reports that it is accelerating its HerpeCide drug development program.
NanoViricides, Inc., a nanomedicine company developing anti-viral drugs, discusses the significance of the strong effectiveness demonstrated by its anti-viral drug candidates in a lethal animal model of dermal herpes infection.
Case Western Reserve researchers are part of an international team that has discovered that a common herpes drug reduces HIV-1 levels — even when patients do not have herpes.
ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it has been granted a Type B meeting with the U.S. Food and Drug Administration (FDA) to discuss its proposal for the design of a Phase 3 trial of ContraVir's lead antiviral candidate, FV-100.
Saint Louis University research findings published in the December issue of Antimicrobial Agents and Chemotherapy report a family of molecules known as nucleotidyltransferase superfamily (NTS) enzyme inhibitors are promising candidates for new herpes virus treatments.
Chimerix, Inc., a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, and ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that the companies have entered into a strategic collaboration for the further clinical development and commercialization of CMX157.
ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it has initiated a pharmacokinetic (PK) study of FV-100, the Company's clinical-stage antiviral for treating shingles.
BioAlliance Pharma SA, an innovative Company specialized in the development of drugs in orphan oncology diseases, today announces an exclusive supply and license agreement for Sitavig® (Acyclovir Lauriad®) with Daewoong Pharmaceutical Co., Ltd. for commercialization rights in South Korea.
People with severe encephalitis - inflammation of the brain - are much more likely to die if they develop severe swelling in the brain, intractable seizures or low blood platelet counts, regardless of the cause of their illness, according to new Johns Hopkins research.
BioAlliance Pharma SA, a Company dedicated to the development of orphan oncology products and supportive care products, has presented the results of the pharmacokinetic and pharmacodynamic study on Sitavig at the 10th EADV spring symposium (European Academy of Dermatology and Venereology) in Cracow (Poland) on May 24, 2013.
The Journal of the Pediatric Infectious Diseases Society today released its June issue, which includes a consensus statement of the global Sentinel Project on Pediatric Drug-Resistant Tuberculosis.
Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Acyclovir Ointment USP, 5%.
Researchers at Albert Einstein College of Medicine of Yeshiva University have discovered a novel strategy for preventing infections due to the highly common herpes simplex viruses, the microbes responsible for causing genital herpes (herpes simplex virus 2) and cold sores (herpes simplex virus 1).
BioAlliance Pharma SA, an innovative Company dedicated to the development of orphan oncology products and to supportive care products, announces the extension of its phase II clinical trial with Validive in the United States in radio/chemotherapy-induced oral mucositis prevention in patients with head and neck cancer.